このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder (URIS-1)

2026年11月10日 更新者:Zuzana Jirásková、General University Hospital, Prague

Peroneal Transcutaneous Neuromodulation in Children With Overactive Bladder: A Prospective, Randomized, Sham-Controlled Clinical Trial

This prospective, randomized, sham-controlled clinical investigation evaluates the efficacy and safety of peroneal transcutaneous electrical neuromodulation (URIS I system) in children aged 7-12 years with wet overactive bladder and daytime urinary incontinence who did not respond or responded insufficiently to standard urotherapy. Participants are randomized 1:1 to active or sham stimulation and receive 12 weekly bilateral sessions of 30 minutes over 12 weeks.

調査の概要

詳細な説明

Investigator-initiated academic study sponsored by the General University Hospital in Prague. The primary objective is to determine the effect of peroneal transcutaneous electrical neuromodulation on the frequency of daytime urinary incontinence in children with overactive bladder. The primary variable is the clinical responder rate at the end of treatment (week 12). Secondary objectives are the effect on micturition frequency, functional bladder capacity, parent- and child-reported symptoms and quality of life (DVISS, PIN-Q, PGI-I), clinician-rated global improvement (CGI-I), and the safety, tolerability and adherence to treatment.

Children are randomized 1:1 (permuted blocks, sealed opaque envelopes) to active stimulation or sham stimulation with the stimulation voltage set to 0 V. Both procedures are identical in preparation, electrode placement, duration and the 4 Hz acoustic signal; the child and the parent are separated from the lower limbs by an opaque screen. Planned sample size: 21 evaluable participants per arm; 47 participants are to be enrolled to allow for approximately 10% attrition.

The URIS I device is supplied by the manufacturer, Stimvia s.r.o., under a loan agreement. The manufacturer is not a sponsor or collaborator of this study.

研究の種類

介入

入学 (推定)

47

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

      • Prague、チェコ、128 08
        • 募集
        • General University Hospital
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

7年~12年 (子)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Children aged 7 to 12 years, boys and girls
  • Wet form of overactive bladder (urgency with daytime urinary incontinence, with or without nocturnal enuresis)
  • At least 8 wet days during waking hours in 2 weeks, based on the wetting diary
  • No or insufficient response to standard urotherapy (ICCS) lasting at least 3 months
  • Ability and willingness of the child and the parent to follow the protocol; signed informed consent

Exclusion Criteria:

  • Severe daytime incontinence (complete wetting in more than 50% of episodes)
  • Anticholinergic treatment for overactive bladder in the last 3 months
  • Neurogenic lower urinary tract dysfunction
  • Congenital malformations of the lower urinary tract (e.g. bladder exstrophy, anorectal malformation)
  • Severe systemic or neurological disease (e.g. cardiac disorders, epilepsy)
  • Local lesions of the lower limbs (skin disease, osteosynthesis material)
  • Peripheral neuropathy of the lower limbs
  • Presence of an electronic implant in the body (e.g., a neurostimulator)
  • Functional constipation during the previous 3 months (Rome III-IV criteria)
  • Symptomatic urinary tract infection

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Active stimulation

Active bilateral peroneal transcutaneous neuromodulation with URIS I, 30 minutes, once a week for 12 weeks.

Bilateral peroneal transcutaneous electrical neuromodulation with the URIS I system. A neutral self-adhesive electrode is placed on the lower abdomen; the optimal stimulation point at the lateral edge of the popliteal fossa is identified by a rhythmic motor response of the leg, and the stimulation voltage is set to the lowest value that evokes this response. Stimulation lasts 30 minutes, once a week for 12 weeks (12 sessions). The device emits a 4 Hz acoustic signal.

偽コンパレータ:Sham stimulation

Sham stimulation with URIS I at 0 V (no stimulation delivered), same procedure, electrode placement, 4 Hz acoustic signal and schedule as the active arm: 30 minutes, once a week for 12 weeks.

Identical preparation, electrode placement and duration as active stimulation, but the stimulation voltage is set to 0 V bilaterally so that no stimulation is delivered. Exposure to active stimulation is limited to the minimum needed to locate the stimulation point. 30 minutes, once a week for 12 weeks (12 sessions). The device emits the same 4 Hz acoustic signal.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Proportion of clinical responders at the end of treatment
時間枠:Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

A clinical responder is a child who meets either or both of the following criteria at the end of treatment:

  1. a reduction of at least 50% in the number of wet days during waking hours over 14 days of the wetting diary compared with baseline;
  2. a PGI-I score of 2 or less rated by both the parent and the child. PGI-I (Patient Global Impression of Improvement) ranges from 1 = very much better to 7 = very much worse.
Week 12 (Visit 3: on the day of the 12th stimulation session or within 2 weeks after it)

二次結果の測定

結果測定
メジャーの説明
時間枠
Change in the number of daytime incontinence episodes per 24 hours
時間枠:Baseline, Week 6, Week 12

Number of incontinence episodes during waking hours per 24 hours, averaged over 14 days of the wetting diary; change from baseline.

Baseline, Week 6, Week 12
Change in the severity of daytime incontinence episodes
時間枠:Baseline, Week 6, Week 12

Severity of incontinence episodes (complete vs. partial wetting) per 24 hours during waking hours over 14 days of the wetting diary; change from baseline.

Baseline, Week 6, Week 12
Change in the number of wet days
時間枠:Baseline, Week 6, Week 12

Number of wet days during waking hours over 2 weeks (a wet day is a day with leakage producing a stain on underwear larger than a 10 CZK coin / 1 EUR coin); change from baseline.

Baseline, Week 6, Week 12
Change in micturition frequency and functional bladder capacity
時間枠:Baseline, Week 6, Week 12

Mean number of voids per 24 hours and mean voided volume (functional bladder capacity) from the 48-hour frequency-volume chart; change from baseline.

Baseline, Week 6, Week 12
Change in DVISS total score (parent-rated)
時間枠:Baseline, Week 6, Week 12

Dysfunctional Voiding and Incontinence Symptom Score total score completed by the parent; change from baseline. Higher scores indicate more severe symptoms.

Baseline, Week 6, Week 12
Change in Bower PIN-Q total score (child-rated)
時間枠:Baseline, Week 6, Week 12

Pediatric Incontinence Questionnaire (PIN-Q) total score completed by the child as a measure of quality of life; change from baseline.

Baseline, Week 6, Week 12
PGI-I score rated by the child and by the parent
時間枠:Week 6, Week 12

Patient Global Impression of Improvement, rated separately by the child and by the parent (1 = very much better to 7 = very much worse).

Week 6, Week 12
CGI-I score rated by the unblinded investigator
時間枠:Week 6, Week 12

Clinical Global Impression of Improvement rated by the principal investigator or co-investigator (1 = very much improved to 7 = very much worse).

Week 6, Week 12
Number, type and severity of treatment-related adverse events
時間枠:From the first stimulation to Week 12

Adverse events (description, severity, onset, resolution, action taken and relationship to neuromodulation) recorded at every stimulation session and visit.

From the first stimulation to Week 12
Adherence to treatment
時間枠:Week 12

Proportion of participants who attend at least 80% of the 12 planned stimulation sessions.

Week 12

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • 主任研究者:Zuzana Jiraskova, MD, FEAPU、General University Hospital, Prague

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年9月3日

一次修了 (推定)

2028年6月1日

研究の完了 (推定)

2028年6月1日

試験登録日

最初に提出

2026年11月10日

QC基準を満たした最初の提出物

2026年11月10日

最初の投稿 (実際)

2026年11月16日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月16日

QC基準を満たした最後の更新が送信されました

2026年11月10日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • Uris_01_2026
  • 000058 (その他の識別子:ISZP)
  • sukls114680/2026 (その他の識別子:State Institute for Drug Control (SUKL))
  • sukl222573/2026 (その他の識別子:State Institute for Drug Control (SUKL))
  • 376/26 A, IB, D, PS (その他の識別子:Ethics Committee, General University Hospital in Prague)
  • 443/26 A, IB (その他の識別子:Ethics Committee, General University Hospital in Prague)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

IPD プランの説明

Individual participant data (IPD) will not be shared to protect patient privacy, as this study evaluates a vulnerable pediatric population and is subject to strict GDPR and institutional data protection regulations.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する